



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

13 Jul 2020 (#33)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- [NOT-OD-20-125](#): Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants
- NIH is launching [Harnessing Data Science for Health Discovery and Innovation in Africa \(DS-I Africa\)](#), an NIH Common Fund program, to explore how advances in data science applied in the African context can spur new health discoveries and catalyze innovation.
- [Fulbright-Fogarty Fellows in Public Health](#) - Fogarty continues its partnership with the Fulbright Program, the flagship international educational exchange program sponsored by the U.S. government, to promote the expansion of research in public health and clinical research in resource-limited settings for medical and graduate students. Application deadline for 2021-2022: 13 October 2020.

Upcoming Deadlines

- [International Bioethics Training](#) 4 August 2020
- [Global Infectious Disease Research Training](#) D43 14 August 2020; D71 28 October 2020
- [HIV Research Training Program for LMIC Institutions](#) 20 August 2020
- [Mobile Health: Technology and Outcomes in LMICs](#) 24 September 2020; AIDS deadline 3 December 2020
- [Fulbright-Fogarty Fellows in Public Health](#) 13 October 2020
- [Emerging Global Leader Award](#) 4 November 2020
- [Global Brain Disorders Research](#) 6 November 2020
- [Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in LMICs](#) 12 November 2020
- [Chronic, Noncommunicable Diseases and Disorders Research Training \(NCD-Lifespan\)](#) D43 13 November 2020
- [Ecology and Evolution of Infectious Diseases Initiative \(EEID\)](#) 18 November 2020

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)

- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

- [NOT-AI-20-059](#): Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
- [NOT-CA-20-082](#): Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19).

Funding Opportunities

1. Tobacco Use and HIV in Low and Middle-Income Countries (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-20-037](#)

Type: U01

Application Due Date: 24 September 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support the development and evaluation of tobacco cessation interventions tailored to HIV-positive populations, including those with comorbidities such as tuberculosis (TB), in low-resource settings in low- and middle-income countries (LMICs). In particular, this FOA aims to bring together transdisciplinary teams of investigators to adapt interventions developed and tested in other challenging settings or low-resource populations and to test their robustness among persons living with HIV (PLWH) in LMICs. Responsive applications must propose research that will be conducted with PLWH in one or more LMICs and will inform efforts to reduce tobacco-related morbidity and mortality among PLWH. Research may also address the behavioral and sociocultural factors and conditions that are associated with tobacco use among PLWH and may also address tobacco-related health disparities among PLWH.

Budget: Application budgets are limited to \$500,000 in direct costs in any one year. The maximum project period is 5 years.

2. Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-21-004](#)

Type: UG3/UH3

Application Due Date: 14 October 2020, by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.

The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase. UH3 phase awards will be awarded after administrative review of eligible UG3 phase awards that have met the scientific milestone and feasibility requirements necessary for UH3 phase implementation. The number of awards is dependent on the availability of funds. The UG3/UH3 application must be submitted as a single application, and applicants should note specific instructions for each phase in this FOA. The total award project period will not exceed 5 years.

Budget: FDA/CDER intends to commit up to \$4,200,000 total for fiscal year 2021 to fund up to three (3) awards in support of this grant program. The scope of the proposed project should determine the project period. The UG3 phase is limited to up to two years and the UH3 phase can request up to four years of support. The total project period for an application submitted in response to this FOA may not exceed five (5) years.

UG3 (up to 2 years): Combined years: up to \$1,400,000 total costs/per award. It is up to the applicant to determine the number of years and budget for the UG3 phase. The application should provide justification for the number of years and budget split among the years if the UG3 phase is anticipated to take more than 1 year. **UH3 (up to 4 years):** Combined years: up to \$2,700,000 total costs/award. It is up to the applicant to determine the number years and budget for the UH4 phase. The application should provide justification for the number of years for the UH3 phase and budget split among the years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105